TLR4 and Parkinson disease: In α-syn contexts relevant to Parkinson’s disease, HXT reduces the TLR4/MyD88 cascade that drives NF-κB/MAPK signalling and NLRP3 inflammasome activation, a central pathogenic axis produced during Parkinson’s disease [42].